Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253305 · ClinicalTrials.gov registry record · Phase 2
Topical Gel Anti-Fungal Agent for Tinea Unguium
A Phase 2 study, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00253305: Completed Phase 2 study, sponsored by MediQuest Therapeutics.
NCT00253305 is a Phase 2 study that has completed, run by MediQuest Therapeutics. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00253305, a Phase 2 study, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). The formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. This study will examine dose-response and agent differences in terms of efficacy and safety. Once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study.
Interventions
- DRUG Organogel of naftifine, 2%
- DRUG Organogel of terbinafine, 2%
- DRUG Organogel of naftifine, 6%
- DRUG Organogel of terbinafine, 6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00253305 record still lists
NCT00253305 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 4 interventions - of which Organogel of naftifine, 2% is the first listed.
NCT00253305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00253305 about?
NCT00253305 is a clinical study titled "Topical Gel Anti-Fungal Agent for Tinea Unguium". The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). The formulation used a...
What is the current status of trial NCT00253305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-09.
What interventions are being tested in trial NCT00253305?
The interventions under investigation include: Organogel of naftifine, 2% (DRUG), Organogel of terbinafine, 2% (DRUG), Organogel of naftifine, 6% (DRUG), Organogel of terbinafine, 6% (DRUG).
Who is sponsoring clinical trial NCT00253305?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00253305's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia